Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide
Go back to Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide| (NASDAQ: MGTX) | Delayed: 13.62 -0.27 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.89 | 52 Week High | $ | |||
| Open | $13.54 | 52 Week Low | $ | |||
| Day High | $13.72 | P/E | N/A | |||
| Day Low | $13.22 | EPS | $ | |||
| Volume | 368,239 | |||||
